Sign inJoin waitlistJoin the waitlist

Ferdinandos Skoulidis

Assistant Professor, Thoracic/Head and Neck Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2013–2014
St Bartholomew's Hospital
2005–2006
Royal Marsden Hospital
2005
Royal Marsden Hospital
2004–2005
Addenbrooke's Hospital
2002–2004
Royal Devon and Exeter Hospital
2001–2002
Doctor of Medicine
1996–2000

Research

Sotorasib for Lung Cancers with KRAS p.G12C Mutation
New England Journal of Medicine · 2021 · First of 26 authors · 1,513 citations
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Cancer Discovery · 2018 · Co-first of 69 authors · 1,415 citations
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase…
Journal of Clinical Oncology · 2019 · 1,075 citations

John Heymach
51 papers
Jianjun Zhang
29 papers · 1 as a fellow
Don Gibbons
25 papers
Anne Tsao
19 papers
Lauren Byers
19 papers
George Blumenschein
18 papers
Marcelo Negrao
17 papers
Tina Cascone
17 papers · 1 as a fellow
Xiuning Le
17 papers
Mehmet Altan
16 papers
Yasir Elamin
16 papers · 1 as a fellow
Carl Gay
14 papers · 3 as a fellow

Grants

Elucidating Roles of the CD24 Ligand in Early Lung Cancer Development, Immune Evasion and Response to KRAS-Targeted Therapy
National Cancer Institute · R01
PI · $669.5K · University of Tx Md Anderson Can Ctr
2026–2031
Targeting Non-Small Cell Lung Cancer Cells and the Adverse Tumor Microenvironment with a Small-Molecule STAT3 Inhibitor
National Cancer Institute · R01
PI · $2M · University of Tx Md Anderson Can Ctr
2023–2028
Dissecting and Targeting Tumor-TME Crosstalk to Forestall Acquired KRASG12C Inhibitor Resistance in NSCLC.
National Cancer Institute · R01
Contact PI · $1.5M · University of Tx Md Anderson Can Ctr
2023–2028
Dissecting and Targeting Mechanisms of Genomic Instability-Triggered Immune Evasion in RBM10-Deficient Non-Small Cell Lung Cancer
National Cancer Institute · R01
Contact PI · $1.5M · University of Tx Md Anderson Can Ctr
2023–2028

Clinical trials

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2022–2027
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2018–2027